MD
Pediatrix Medical Group, Inc.
MD offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over MD overall, supported by stronger modeled upside and stronger valuation.
MD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
MD's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
MD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $19.61 | -38% |
| Fair | 13x | $23.57 | -25% |
| Forward | 13x | $31.40 | — |
| Current | 17x | $31.40 | — |
| Expensive | 19x | $34.33 | +9.3% |
Historical ranges are pointers, not guarantees.
MD has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
MD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect MD's earnings to grow and its profitability to improve, with its revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.45 | +33% |
| Q3 2026 | $1.84 | -3.7% |
| Q2 2026 | $2.09 | +61% |
| Q1 2026 | $2.06 | +$3.06 |
| Q4 2025 | $1.94 | +$3.13 |
| Q3 2025 | $1.91 | +$4.97 |
| Q2 2025 | $1.30 | +$4.33 |
| Q1 2025 | -$1.00 | -$0.15 |
| Q4 2024 | -$1.19 | -$0.46 |
MD has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
MD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $501.4M | +1.7% |
| Q2 2026 | $487.8M | +4% |
| Q1 2026 | $476.2M | +3.9% |
| Q4 2025 | $493.8M | -1.7% |
| Q3 2025 | $492.9M | -3.6% |
| Q2 2025 | $468.8M | -7% |
| Q1 2025 | $458.4M | -7.4% |
| Q4 2024 | $502.4M | +1.2% |
MD's revenue fell from its 2019 peak and has held roughly level since: $501M last quarter, up 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -0.8 points |
| Q2 2026 | 12% | -1.1 points |
| Q1 2026 | 8.8% | +1.8 points |
| Q4 2025 | 9.9% | +2.1 points |
| Q3 2025 | 14% | +7.2 points |
| Q2 2025 | 13% | +44 points |
| Q1 2025 | 7% | +3.8 points |
| Q4 2024 | 7.8% | +30 points |
MD has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over MD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
MD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $112.9M | -14% |
| Q2 2026 | $123.9M | -6.6% |
| Q1 2026 | -$136.1M | -$15.3M |
| Q4 2025 | $108.8M | -16% |
| Q3 2025 | $131.9M | +54% |
| Q2 2025 | $132.7M | +33% |
| Q1 2025 | -$120.8M | +$9.8M |
| Q4 2024 | $129.6M | +115% |
MD still generates free cash flow, though less than at its 2020 peak: $210M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over MD on cash flow, with more consistent year-over-year improvement.
MD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -1.7M shares |
| 1 year | -6.9% | -5.9M shares |
| 3 years | -3.9% | -3.2M shares |
| 5 years | -7.4% | -6.4M shares |
| Available history | -4.3% | -3.6M shares |
MD has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $83M |
| Q2 2026 | $42.7M |
| Q1 2026 | $21.5M |
| Q4 2025 | $64M |
| Q3 2025 | $20.9M |
| Q2 2025 | $209,000 |
| Q1 2025 | $1.6M |
| Q4 2024 | $643,000 |
MD spent $211M buying back its own shares over the past year, about nine times what it spent the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
MD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 2.0x | Moderate |
| Q1 2024 | 2.9x | Moderate |
| Q4 2023 | 12.9x | High |
MD has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
MD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.7 | Overbought |
| Stochastic | 80.5 | Overbought |
MD's weekly RSI is 78 (overbought) and its Stochastic is 81 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
MD PE vs Healthcare Sector
| Metric | MD | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 72 | 29 | 43 pts above |
MD has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
MD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.5 | 10% above |
| 20 week MA | $27.3 | 15% above |
| 50 week MA | $24.0 | 31% above |
| 100 week MA | $19.6 | 60% above |
| 200 week MA | $15.6 | 101% above |
MD has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
MD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.2 | $23.9 | -12% |
| 2021 | $23.9 | $27.6 | +15% |
| 2022 | $27.6 | $14.9 | -46% |
| 2023 | $14.9 | $9.30 | -38% |
| 2024 | $9.30 | $13.5 | +45% |
| 2025 | $13.5 | $21.9 | +62% |
| 2026 YTD | $21.9 | $31.4 | +44% |
MD has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.